依达拉奉对急性脑梗死患者血清中白细胞介素-1、-17A和高迁移率族蛋白B1的影响

发布时间：2018-06-08 10:48

本文选题：急性脑梗死 + 白细胞介素-　；参考：《中国老年学杂志》2017年16期

【摘要】：目的关注急性脑梗死患者应用依达拉奉的治疗效果,观察其对血清中白细胞介素(IL)-1、-17A和高迁移率族蛋白(HMG)B1的影响。方法 70例急性脑梗死患者随机分为观察组和对照组各35例。对照组采用常规治疗方法,观察组在常规治疗的基础上加用依达拉奉注射液30 mg(溶于100 ml生理盐水),2次/d,共治疗14 d。均留取治疗前、后的空腹静脉血,应用酶联免疫吸附(ELISA)法检测血清中IL-1、IL-17A和HMGB1的表达。结果观察组治疗后显效率显著优于对照组,两组治疗后血清中IL-1、IL-17A和HMGB1的表达均下降(P0.05),观察组下降值明显高于对照组(P0.05)。结论急性脑梗死患者应用依达拉奉治疗效果明显,同时能有效下调血清中IL-1、IL-17A和HMGB1的水平,对微环境的调节作用理想。
[Abstract]:Objective to observe the effect of Edaravone on serum interleukin-1 (IL-1) -17A and high mobility group protein (HMGN) B1 in patients with acute cerebral infarction. Methods 70 patients with acute cerebral infarction were randomly divided into observation group (n = 35) and control group (n = 35). The control group was treated with routine therapy, and the observation group was treated with Edaravone injection 30 mg / d for 14 days. Fasting venous blood was collected before and after treatment, and the expression of IL-1IL-17A and HMGB1 in serum was detected by enzyme-linked immunosorbent assay (Elisa). Results the effective rate after treatment in the observation group was significantly better than that in the control group. After treatment, the expression of IL-1 IL-17A and HMGB1 in the serum of the two groups decreased significantly (P 0.05), and the value of the decrease in the observation group was significantly higher than that in the control group (P 0.05). Conclusion Edaravone is effective in the treatment of acute cerebral infarction patients, and can effectively down-regulate the levels of IL-1and HMGB1 in serum, and the effect of Edaravone on microenvironment is ideal.
【作者单位】：锦州医科大学附属第一医院神经内科;辽阳市中心医院神经内三科;
【基金】：辽宁省科技厅自然科学基金项目(No.201602313)
【分类号】：R743.3

【相似文献】